Medtech Strategic/Start-Up Partnerships: Structuring For Success

May 28 2014

According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.

Tough times call for creativity. The contraction of the number of venture firms and a significant decrease in the quantity of funds available for investing in medtech mean that entrepreneurs and venture capitalists need to find new ways to fund the start-ups looking to advance technologies that will improve patients’ health and the delivery of health care, too. Venture capitalists have turned their lonely eyes to the medical device strategics with the hope that they’ll step in to fill the funding gap. It’s in the best interest of the strategics, the thinking goes, because innovation that’s stifled today for lack of capital leads to a lack of growth opportunities for the large product companies five years from now.

Start-ups and market leaders make fitting partners. It’s almost a universal truth that most product innovation comes from start-ups. Start-ups...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Neuromodulation Is Booming – But Shocks Could Still Come

Oct 22 2025

• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Deals In Depth: September 2025

Oct 13 2025

• By Deanna Kamienski and Maureen Riordan

Eight $1bn+ alliances were penned in September, and four exceeded $2bn. In the top alliance by deal value, Monte Rosa Therapeutics will apply its AI-enabled QuEEN platform for the discovery and development of novel molecular glue degraders for immune-mediated diseases.

ALS Drug Development Case Studies: MediciNova And Coya Therapeutics

Oct 08 2025

• By David Wild

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

Oct 06 2025

• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

China’s Medtech Policies Prompt Reflection Among Global Companies As Local Players Adapt

Oct 20 2025

• By Ashley Yeo

Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.